Drug updated on 10/24/2024
Dosage Form | Injection (intramuscular; 50 units/vial, 100 units/vial) |
Drug Class | Acetylcholine release inhibitorsr and neuromuscular blocking agents |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients
- Indicated for the treatment of cervical dystonia in adult patients
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- OnabotulinumtoxinA-20 U: Likely has a higher participant-assessed success rate at week four compared to placebo (Risk Ratio (RR) 19.45, 95% Confidence Interval (CI) 8.60 to 43.99; 575 participants, 4 studies; moderate-certainty evidence) and a higher physician-assessed success rate (RR 17.10, 95% CI 10.07 to 29.05; 1339 participants, 7 studies; moderate-certainty evidence).
- AbobotulinumtoxinA-50 U: Demonstrates a higher participant-assessed success rate at week four compared to placebo (RR 21.22, 95% CI 7.40 to 60.56; 915 participants, 6 studies; high-certainty evidence) and a higher physician-assessed success rate (RR 14.93, 95% CI 8.09 to 27.55; 1059 participants, 7 studies; moderate-certainty evidence).
- IncobotulinumtoxinA-20 U: Likely has a higher participant-assessed success rate at week four compared to placebo (RR 66.57, 95% CI 13.50 to 328.28; 547 participants, 2 studies; moderate-certainty evidence) and a higher physician-assessed success rate (RR 134.62, 95% CI 19.05 to 951.45; 547 participants, 2 studies; moderate-certainty evidence).
- OnabotulinumtoxinA-20 U: Probably has a higher incidence of major adverse events compared to placebo (Peto Odds Ratio (OR) 3.62, 95% CI 1.50 to 8.74; 1390 participants; 8 studies; moderate-certainty evidence). There may be no difference in any adverse events (RR 1.14, 95% CI 0.89 to 1.45; 1388 participants; 8 studies; low-certainty evidence).
- AbobotulinumtoxinA-50 U: Probably has more major adverse events compared to placebo (Peto OR 3.36, 95% CI 0.88 to 12.87; 1294 participants; 7 studies; moderate-certainty evidence). Any adverse event may be more common compared to placebo (RR 1.25, 95% CI 1.05 to 1.49; 1471 participants; 8 studies; low-certainty evidence).
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Daxxify (daxibotulinumtoxinA-lanm) Prescribing Information. | 2023 | Revance Therapeutics Inc., Newark, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Botulinum toxin type A for facial wrinkles | 2021 | The Cochrane Database of Systematic Reviews |